Investigational Drug Information for Tropifexor
What is the drug development status for Tropifexor?
Tropifexor is an investigational drug.
There have been 7 clinical trials for Tropifexor.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 9th 2015.
The most common disease conditions in clinical trials are Fatty Liver, Non-alcoholic Fatty Liver Disease, and Liver Cirrhosis. The leading clinical trial sponsors are Novartis Pharmaceuticals, Allergan, and [disabled in preview].
Summary for Tropifexor
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 533 |
| WIPO Patent Applications | 195 |
| Japanese Patent Applications | 31 |
| Clinical Trial Progress | Phase 2 (2015-09-09) |
| Vendors | 40 |
Recent Clinical Trials for Tropifexor
| Title | Sponsor | Phase |
|---|---|---|
| Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH) | Novartis Pharmaceuticals | Phase 2 |
| The Purpose of This Study is to Investigate Safety and Tolerability of Tropifexor. | Novartis Pharmaceuticals | Phase 1 |
| Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis. | Novartis Pharmaceuticals | Phase 2 |
Clinical Trial Summary for Tropifexor
Top disease conditions for Tropifexor
Top clinical trial sponsors for Tropifexor
US Patents for Tropifexor
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Tropifexor Development Update and Market Projection
Tropifexor, also known as LJN452, is an oral, non-bile-acid farnesoid X receptor agonist developed by Novartis for metabolic dysfunction-associated steatohepatitis, formerly called nonalcoholic steatohepatitis, and cholestatic liver diseases. Public development activity has not produced an approval, commercial launch, or validated late-stage registration path. The base-case commercial projection is therefore zero near-term revenue. A meaningful value recovery would require Novartis or another sponsor to restart clinical development and establish a differentiated safety profile against resmetirom and emerging MASH therapies.
What is the current development status of tropifexor?
Tropifexor remains an investigational drug with no FDA, European Medicines Agency, or other major-market approval.
Novartis evaluated tropifexor in nonalcoholic steatohepatitis and primary biliary cholangitis. The program generated evidence of pharmacodynamic activity, including reductions in liver fat and liver enzymes, but development was constrained by class-related tolerability concerns, particularly pruritus and lipid changes.
Tropifexor development timeline
| Period | Development event | Commercial significance |
|---|---|---|
| 2015-2016 | Early clinical studies initiated in liver disease | Established FXR target engagement |
| 2018-2019 | Phase 2 NASH data reported | Demonstrated reductions in liver fat and alanine aminotransferase |
| 2019-2021 | Additional studies evaluated dose, safety, and liver outcomes | Pruritus and lipid effects remained relevant liabilities |
| 2021 onward | No visible transition into a pivotal registration program | Reduced probability of independent commercialization |
| 2024 | No FDA approval or marketed product | No product revenue or Orange Book exclusivity |
Clinical studies evaluated multiple once-daily doses, including low-dose regimens intended to preserve FXR activity while limiting adverse events. Tropifexor’s clinical profile was consistent with the broader FXR class: biological activity was observable, but tolerability and long-term outcome requirements limited development economics.
What clinical evidence supports tropifexor in MASH and NASH?
The principal clinical opportunity was MASH, where FXR activation can influence bile-acid signaling, hepatic inflammation, fibrosis, and metabolic pathways.
In a Phase 2 study, tropifexor reduced liver fat measured by magnetic resonance imaging-based techniques and lowered alanine aminotransferase in selected dose groups. The study was short and was not designed to establish long-term fibrosis benefit or clinical outcomes such as decompensation, transplantation, or liver-related mortality.
Key clinical strengths
- Oral, once-daily administration.
- High potency at low doses.
- Measurable liver-fat reduction.
- Potential activity across steatohepatitis and cholestatic liver disease.
- Mechanistic relevance to bile-acid and hepatic metabolic signaling.
Key clinical weaknesses
- Pruritus, a recognized FXR-class adverse event.
- Potential low-density lipoprotein cholesterol elevation.
- Limited evidence of durable fibrosis improvement.
- No demonstrated reduction in liver-related clinical events.
- Competition from approved and late-stage non-FXR therapies.
The clinical bar has risen since early tropifexor studies. Resmetirom received FDA approval in March 2024 for adults with noncirrhotic MASH with moderate-to-advanced fibrosis, in conjunction with diet and exercise. This gives developers a commercial benchmark for histologic efficacy, labeling, safety management, and payer positioning (U.S. Food and Drug Administration, 2024).
What is the FDA regulatory status of tropifexor?
Tropifexor has no FDA approval, tentative approval, breakthrough designation publicly linked to a marketing application, or approved label.
There is no publicly established New Drug Application for tropifexor. The candidate therefore has no approved indication, approved dosage, approved manufacturing process, or FDA-recognized product exclusivity.
| Regulatory category | Tropifexor status |
|---|---|
| FDA approval | None |
| Approved indication | None |
| Approved dosage form | None |
| New Drug Application approval | None publicly identified |
| Orphan-drug approval | None publicly identified |
| Orange Book listing | None |
| Commercial launch | None |
What patents protect tropifexor?
Tropifexor is expected to have been covered by Novartis-originated composition-of-matter, pharmaceutical-composition, and therapeutic-use patent families. The public commercial position, however, is weaker than that of an approved product because no issued patent has been paired with an FDA-approved reference drug.
Likely patent categories
| Patent category | Relevance to tropifexor |
|---|---|
| Composition of matter | Primary protection for the LJN452 chemical entity |
| Salt, polymorph, and solid-state claims | May protect drug substance properties |
| Pharmaceutical composition | May cover oral formulations and excipient combinations |
| Method of treatment | May cover MASH, NASH, PBC, or other liver conditions |
| Combination therapy | May cover use with metabolic or lipid-lowering agents |
| Manufacturing process | May create route-specific production barriers |
Because tropifexor is not approved, it has no Orange Book-listed patents under the FDA’s approved-drug framework. That distinction matters. Patent rights may exist independently, but they do not currently create an FDA-based generic launch barrier.
When does tropifexor lose exclusivity?
There is no commercially relevant loss-of-exclusivity date because tropifexor has not reached approval. Any composition-of-matter or use patents would need to be assessed by jurisdiction and patent family rather than through an Orange Book expiration date.
A generic company could not file an ordinary abbreviated new drug application referencing tropifexor unless the FDA first approved tropifexor as a reference product. A Paragraph IV challenge is therefore not a current commercial event.
What is the Orange Book status of tropifexor?
Tropifexor is not listed in the FDA Orange Book as an approved drug product. It has no reference-listed drug status, no Orange Book patent listing, and no regulatory exclusivity period that would delay an ANDA.
The absence of an Orange Book listing does not eliminate private patent risk. A future sponsor would need to conduct a freedom-to-operate review covering U.S. composition, formulation, use, process, and combination patents.
How strong is the tropifexor patent estate?
The patent estate is commercially unproven rather than clearly weak or strong.
Composition-of-matter protection, if still enforceable, would normally provide the most valuable barrier. Method-of-use patents for MASH or PBC would face greater validity and infringement risk because the relevant disease concepts, biomarkers, and treatment methods are crowded. Formulation and manufacturing patents would usually provide narrower protection and would be easier for a competitor to design around.
Patent-strength assessment
| Factor | Assessment |
|---|---|
| Composition protection | Potentially high value if unexpired and enforceable |
| Formulation protection | Likely narrower than composition claims |
| Method-of-use protection | Moderate or uncertain commercial strength |
| Orange Book leverage | None while unapproved |
| Generic litigation exposure | Low today because no reference product exists |
| Re-entry litigation risk | Material if development resumes |
| Manufacturing barriers | Dependent on route-specific claims and process complexity |
What formulation patents protect tropifexor?
No approved commercial formulation has been disclosed through an FDA label. Clinical development used oral formulations, but the commercial scope of any formulation patents cannot be inferred from clinical-trial dosing alone.
Potential formulation claims could cover:
- Low-dose oral capsules or tablets.
- Solid dispersions or improved dissolution systems.
- Specific crystalline forms.
- Stability-enhancing excipient systems.
- Combination formulations with lipid-lowering or metabolic drugs.
A formulation-only patent would not necessarily prevent a competitor from developing a different oral formulation of the same active ingredient. A valid composition-of-matter patent would provide broader protection.
What patent litigation affects tropifexor?
No major publicly reported U.S. Hatch-Waxman litigation involving tropifexor has established a current generic-entry dispute. That outcome is consistent with the drug’s unapproved status.
No settlement agreement governing generic entry has been publicly associated with tropifexor. No biosimilar litigation is relevant because tropifexor is a small molecule, not a biologic.
Which companies are challenging tropifexor?
No company is currently known to be challenging tropifexor through a Paragraph IV ANDA filing. The competitive threat comes from substitute therapies rather than direct generic competition.
Competitive therapies
| Product or class | Company | Status | Competitive effect |
|---|---|---|---|
| Resmetirom | Madrigal Pharmaceuticals | FDA-approved for MASH with fibrosis | Sets efficacy and reimbursement benchmark |
| Semaglutide | Novo Nordisk | Metabolic and obesity indications; liver-disease development | Competes through weight loss and metabolic benefit |
| Tirzepatide | Eli Lilly | Obesity and diabetes indications; liver-disease development | Potential broad metabolic positioning |
| Lanifibranor | Inventiva | Clinical development | Direct oral MASH competition |
| Pemvidutide | Altimmune | Clinical development | Weight loss and liver-disease positioning |
| Obeticholic acid | Intercept Pharmaceuticals | MASH program discontinued; approved in some jurisdictions for PBC before withdrawal actions | Validated FXR mechanism but highlighted safety and regulatory risk |
Obeticholic acid’s regulatory history weakened the commercial case for undifferentiated FXR agonists. Tropifexor would require a meaningful advantage in pruritus, lipid effects, fibrosis efficacy, or combination use.
What is the market projection for tropifexor?
The base-case forecast is no revenue through the near term because the candidate has no approved indication or active late-stage commercial program. A relaunch scenario would depend on a new sponsor, a redesigned clinical strategy, and evidence that tropifexor can overcome FXR-class limitations.
Scenario-based revenue projection
| Scenario | Development assumption | Peak annual revenue potential |
|---|---|---|
| Base case | No clinical restart or commercial development | $0 |
| Relaunch case | Phase 2 restart followed by focused approval in MASH or PBC | $250 million-$750 million |
| Upside case | Strong fibrosis data, improved tolerability, global partnership | $1 billion-$2 billion |
| Downside case | Pruritus, LDL elevation, or lack of fibrosis benefit persists | $0 |
These are analytical scenarios, not company guidance. The addressable MASH population is large, but the treated market will depend on fibrosis staging, diagnosis rates, payer restrictions, liver-biopsy or noninvasive-test requirements, and competition from metabolic therapies.
A successful tropifexor launch would likely require one of three positions:
- A safer FXR profile than obeticholic acid and other agonists.
- Combination use with an approved metabolic or antifibrotic therapy.
- A differentiated cholestatic-liver-disease indication where the clinical benefit-risk profile is more favorable.
Without one of those positions, tropifexor would face difficult pricing and adoption conditions against resmetirom and incretin-based therapies.
What generic launch risks exist for tropifexor?
Near-term generic launch risk is low because there is no approved reference product. The more important risk is development obsolescence: a revived tropifexor program could be commercially displaced before approval by better-established MASH therapies.
If tropifexor were approved, launch timing would depend on:
- Remaining composition-of-matter patent life.
- Regulatory exclusivity.
- Orange Book listings.
- Patent settlement terms.
- Formulation and process patents.
- Whether the approved indication supports a skinny-label generic strategy.
Because the candidate has no current approval, there is no reliable generic-entry date.
How does tropifexor compare with resmetirom?
Resmetirom has a substantially stronger current commercial position because it has FDA approval, a defined indication, a regulatory label, and a launch infrastructure. Tropifexor has a mechanistic advantage as a potent FXR agonist but lacks demonstrated market access and late-stage validation.
| Metric | Tropifexor | Resmetirom |
|---|---|---|
| Mechanism | FXR agonist | Thyroid hormone receptor-beta agonist |
| FDA status | Investigational | Approved in 2024 |
| MASH indication | None | Approved for noncirrhotic MASH with moderate-to-advanced fibrosis |
| Commercial revenue | None | Commercially launched |
| Orange Book status | None | Approved-product framework applies |
| Main safety concern | Pruritus and lipid effects | Drug interactions, liver and gallbladder-related warnings, thyroid effects |
| Development risk | High | Lower after approval |
| Market position | Option value | First approved therapy in its segment |
What licensing deals involve tropifexor?
No major publicly disclosed third-party licensing transaction has established an active commercial partner for tropifexor. Novartis appears to have been the principal developer. The absence of a visible licensing deal reduces evidence that an external company has committed capital to late-stage development.
A future transaction would likely be structured around regional rights, a co-development agreement, or an option deal contingent on renewed proof-of-concept data.
Key Takeaways
- Tropifexor is an investigational oral FXR agonist developed primarily by Novartis.
- It has no FDA approval, marketed formulation, Orange Book listing, or product revenue.
- Phase 2 studies showed liver-fat and enzyme activity but did not establish long-term fibrosis or clinical-outcome benefit.
- Pruritus and lipid effects remain central class risks.
- No current Paragraph IV challenge, biosimilar dispute, or generic settlement is publicly established.
- Resmetirom materially raises the commercial and evidentiary bar for any tropifexor revival.
- The base-case market forecast is $0; a successful relaunch could support estimated peak sales of $250 million to $750 million, with upside above $1 billion only under strong efficacy and tolerability assumptions.
FAQs
Is tropifexor approved for NASH or MASH?
No. Tropifexor has no FDA-approved indication for NASH, MASH, primary biliary cholangitis, or another disease.
Does tropifexor have an Orange Book patent expiration date?
No. Tropifexor is not an approved Orange Book product and therefore has no Orange Book patent expiration date.
Can generic companies launch tropifexor?
Not through a conventional ANDA pathway today because there is no approved tropifexor reference product. A future approval could create a later generic pathway subject to patent and exclusivity protections.
Is tropifexor a biosimilar risk?
No. Tropifexor is a small-molecule drug candidate. Biosimilar regulation applies to biologics, not to tropifexor.
Could tropifexor still become a commercial MASH drug?
Yes, but only after a substantial development restart. The program would need new clinical evidence showing durable fibrosis benefit, manageable pruritus and lipid effects, and a market position against resmetirom and incretin-based therapies.
References
- U.S. Food and Drug Administration. (2024). FDA approves first treatment for patients with liver scarring due to fatty liver disease. https://www.fda.gov
- ClinicalTrials.gov. (n.d.). Study of LJN452 in patients with non-alcoholic steatohepatitis. U.S. National Library of Medicine. https://clinicaltrials.gov
- ClinicalTrials.gov. (n.d.). Clinical studies of tropifexor in liver disease. U.S. National Library of Medicine. https://clinicaltrials.gov
- Trauner, M., Gulamhusein, A., Hameed, B., et al. (2022). Tropifexor in nonalcoholic steatohepatitis: Clinical activity and safety findings from a randomized trial. Hepatology.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
More… ↓
